Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766154 | 0.93 | PIK3CD (0.42) | NPC1RAB9AHPGDSTING1FKBP1A | |
| SCHEMBL6020606 | 0.89 | STING1 (0.44) | HPGDSTING1PDGFRAKITACHE | |
| SCHEMBL6021540 | 0.88 | STING1 (0.46) | STING1TDP1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL6021255 | 0.88 | STING1 (0.46) | STING1TDP1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL6020839 | 0.86 | STING1 (0.47) | STING1TDP1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL6021329 | 0.84 | STING1 (0.47) | STING1TDP1PLK1DYRK1AACHE | |
| SCHEMBL6021022 | 0.82 | STING1 (0.49) | STING1KDM4EALDH1A1PLK1DYRK1A | |
| SCHEMBL6020201 | 0.80 | KMT2A (0.51) | STING1KMT2APDGFRAPDGFRBDYRK1A | |
| SCHEMBL4768114 | 0.80 | KMT2A (0.51) | STING1KMT2APDGFRAPDGFRBDYRK1A | |
| SCHEMBL6021010 | 0.80 | KMT2A (0.51) | STING1KMT2APDGFRAPDGFRBDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287469-A1 | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation | DIACOVO THOMAS G | 2008-11-20 | — | — | US | claimed |
| EP-1885356-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2008-02-13 | — | — | EP | claimed |
| WO-2006089106-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2006-08-24 | — | — | WO | claimed |
| EP-1636210-A1 | CYCLOALKYL AND HETEROCYCLOALKYL SUBSTITUTED BENZOTHIOPHENES AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2006-03-22 | — | — | EP | claimed |
| US-20050020630-A1 | Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents | CONNOLLY MICHAEL KEVIN (US) | 2005-01-27 | — | — | US | claimed |
| WO-2004108713-A1 | CYCLOALKYL AND HETEROCYCLOALKYL SUBSTITUTED BENZOTHIOPHENES AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | claimed |
| US-20080287469-A1 | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation | DIACOVO THOMAS G | 2008-11-20 | — | — | US | disclosed |
| EP-1885356-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006089106-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2006-08-24 | — | — | WO | disclosed |
| EP-1636210-A1 | CYCLOALKYL AND HETEROCYCLOALKYL SUBSTITUTED BENZOTHIOPHENES AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050020630-A1 | Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents | CONNOLLY MICHAEL KEVIN (US) | 2005-01-27 | — | — | US | disclosed |
| WO-2004108713-A1 | CYCLOALKYL AND HETEROCYCLOALKYL SUBSTITUTED BENZOTHIOPHENES AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020630-A1 | Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents | MALT1, CYP1B1, WEE2 | NPC1 1571/4885RAB9A 4333/4885HPGD 2531/4885 |
| US-20080287469-A1 | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation | PI4KB, PIK3CA, PI4KA | NPC1 3415/4885RAB9A 2159/4885HPGD 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.